Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Glaucoma 9
2.1.2 Age-Related Macular Degeneration 9
2.1.3 Diabetic Macular Edema 10
2.1.4 Diabetic Retinopathy 10
2.1.5 Dry Eye Syndrome 10
2.2 Symptoms 11
2.3 Etiology and Pathophysiology 13
2.3.1 Etiology 13
2.3.2 Pathophysiology 15
2.4 Co-morbidities and Complications 18
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 19
2.5.1 Glaucoma 19
2.5.2 Age-Related Macular Degeneration 20
2.5.3 Diabetic Macular Edema 22
2.5.4 Diabetic Retinopathy 22
2.5.5 Dry Eye Syndrome 24
2.6 Treatment 26
3 Key Marketed Products 29
3.1 Overview 29
3.2 Lucentis (ranibizumab) 29
3.3 Eylea (aflibercept) 30
3.4 Avastin (bevacizumab) 31
3.5 Restasis (cyclosporine) 32
3.6 Alphagan (brimonidine tartrate) 34
3.7 Lumigan (bimatoprost) 35
3.8 Xalatan (latanoprost) 36
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Pipeline Development Landscape 38
4.3 Mechanisms of Action in the Pipeline 41
4.4 Clinical Trials 43
4.4.1 Failure Rate 43
4.4.2 Clinical Trial Duration 47
4.4.3 Clinical Trial Size 51
4.4.4 Aggregate Clinical Program Size 55
4.4.5 Conclusion 59
5 Multi-Scenario Market Forecast to 2022 60
5.1 Overall Market Size 60
5.2 Generic Penetration 61
5.3 Revenue Forecast by Molecular Target 62
5.3.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) 62
5.3.2 Antihistamines (H1 Receptor) 63
5.3.3 Anti-inflammatories (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) 64
5.3.4 IOP-Lowering (Prostaglandins/Beta Blockers/Rho Kinase Signaling Pathway) 65
5.3.5 Assessment of Key Pipeline Products 65
6 Company Analysis and Positioning 71
6.1 Revenue and Market Share Analysis by Company 72
6.1.1 Novartis – Will Pipeline Product Approvals Offset the Patent Expiry of Lucentis? 77
6.1.2 Bayer – Growing Revenues for Eylea Set to Increase Bayer’s Revenue 78
6.1.3 Regeneron – Growing Revenues for Eylea Will Make it the Top Selling Ophthalmology Drug 79
6.1.4 Roche – Gradual Decline in Revenues Due to Lucentis Patent Expiries and Uptake of Generics 80
6.1.5 Ophthotech – Pipeline Product Approval will Result in Blockbuster Status Within the Forecast Period 81
6.1.6 Spark Therapeutics – Pipeline Product Approval to Resulting in Large Revenues in a Short Space of Time 82
6.1.7 Santen – Patent Expiration of Eylea to Cause Gradual Decline in Revenue 82
6.2 Company Landscape 84
6.3 Marketed and Pipeline Portfolio Analysis 85
7 Strategic Consolidations 88
7.1 Licensing Deals 88
7.1.1 Deals by Region, Year and Value 88
7.1.2 Deals by Stage of Development and Value 90
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 91
7.1.4 Table for Licensing Deals Valued Above $100m 93
7.2 Co-development Deals 94
7.2.1 Deals by Region, Year and Value 94
7.2.2 Deals by Stage of Development and Value 96
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 96
7.2.4 Table for Co-development Deals Valued Above $100m 98
8 Appendix 99
8.1 References 99
8.2 Table of All Clinical Stage Pipeline Products 107
8.3 Abbreviations 146
8.4 Disease List 147
8.5 Methodology 147
8.5.1 Coverage 147
8.5.2 Secondary Research 147
8.5.3 Market Size and Revenue Forecasts 148
8.5.4 Pipeline Analysis 148
8.5.5 Competitive Landscape 149
8.6 Contact Us 149
8.7 Disclaimer 149